MedTrace Logo

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-08-22

Study results available
· View outcomes & findings →

Summary

This is a prospective, double-blind, placebo-controlled, randomized, single-center (North Florida- South Georgia VA Medical Center) study. The study objective is to determine if ranolazine improves angina symptoms at 4 months compared with placebo among stable coronary artery disease patients who have demonstrable myocardial ischemia, but who do not undergo revascularization

Conditions

  • Angina

Interventions

DRUG

Ranolazine

Ranolazine 500mg tablet 1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks

DRUG

Sugar pill

1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • North Florida Foundation for Research and Education

    lead OTHER

Principal Investigators

  • Anthony A Bavry, MD, MPH · NorthFlorida/South Georgia Veterans Health System, Gainesville, FL 32608

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-05-31
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02265796 on ClinicalTrials.gov